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Introduction
Regions of low/insufficient oxygen (hypoxia) are a pathophysio-
logical feature of most solid tumors (1). It has been demonstrated 
conclusively that patients with significant levels of tumor hypoxia 
have a worse prognosis irrespective of treatment modality (2–4). 
Within a tumor, gradients of oxygen concentrations exist, which 
are likely to reach complete anoxia in avascular areas (5, 6). Cells 
exposed to severe hypoxia (<0.1% O2) are particularly radiore-
sistant and induce a replication stress–mediated DNA damage 
response (DDR), which includes stabilization and activation of the 
p53 tumor suppressor (7). Replication stress refers to the slowing 
or stalling of replication forks (8). Importantly, hypoxia induces a 
DDR in the absence of detectable DNA damage (9). p53 is rapidly 
stabilized and activated in response to a wide variety of cellular 
stresses, including DNA damage, oncogene expression, nutrient 
deprivation, ribosomal dysfunction, and hypoxia (<0.1% O2) (10). 
Tumor hypoxia is potentially one of the earliest driving forces 
to mutate p53 function during tumorigenesis (11). The majority 
of human cancers (over 50%) have lost WT p53 function due to 
mutations in the DNA-binding domain (DBD) of the protein (10, 
12). We recently demonstrated that even mild levels of hypoxia 
(2% O2) combined with oncogene-induced replication stress can 
lead to DDR signaling and that this can occur before the accumu-
lation of DNA damage (7).
Under conditions of hypoxia-induced replication stress, 
p53 is phosphorylated and stabilized by the ATR and, to a 
lesser extent, ATM kinases (9, 13). In addition, p53 stabiliza-
tion is facilitated by decreased expression of MDM2 and/or 
by phosphorylation of MDMX E3 ubiquitin ligases (14, 15). 
Once activated by hypoxia, p53 induces apoptosis through 
the intrinsic pathway (16, 17) and requires the transcriptional 
activity of p53 (18, 19). However, the exact p53 target genes 
responsible for apoptosis in hypoxia remain poorly character-
ized. Isolated reports exist, which describe the involvement of 
known proapoptotic targets, such as PUMA or BAD, in hypoxia- 
induced and p53-dependent apoptosis, although these tend to 
be restricted to specific cell lines/types, for example, cardio-
myocytes (20). In contrast, a number of reports demonstrate 
that genes such as PUMA, BAX, or DR5 are not induced by p53 
in various cancer cell lines during hypoxia-induced apopto-
sis (18, 21, 22). Previous studies have suggested that p53 acts 
predominantly as a transrepressor rather than a transactivator 
during hypoxia (18–21). However, few targets of p53-mediated 
transrepression have been reported (18–21). Interestingly, recent 
studies investigating the tumor-suppressive function of p53 
demonstrated that the most characterized p53 targets crucial for 
DNA damage–induced cell cycle arrest, senescence, or apopto-
sis (p21, PUMA, NOXA) appear to be dispensable for suppress-
ing tumorigenesis (23–25). Instead, p53 targets involved in reg-
ulation of energy metabolism, ROS production, and autophagy 
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hypoxia (18). Instead, a number of other p53 targets were iden-
tified, of which the most significant are shown in Figure 1C  
(http://www.ncbi.nlm.nih.gov/geo/; accession number GSE53893). 
Notably and in contrast to our previous study in myc/ras- 
transformed mouse embryonic fibroblasts, we did not observe 
significant levels of p53-mediated gene repression (18). PHLDA3, 
one of the most significantly induced genes in hypoxia, was pre-
viously identified as 1 of 14 genes critical for p53-mediated tumor 
suppression (23). This led us to ask whether any of the other p53 
targets identified by Brady et al. were also hypoxia regulated. 
PHLDA3 stood out as the most hypoxia inducible from this group 
of 14 genes; however, KN motif and ankyrin repeat domains 3 
(KANK3), ABHD4, and DEF6 were also potential p53 targets in 
hypoxia, with some cell line dependence (Figure 1D and Sup-
plemental Figure 1, C–E). GLUT1 served as hypoxia-inducible 
control and BAX as a typical DNA damage–inducible p53 target. 
Together, these data support our hypothesis that p53 induces a 
stress-specific transcriptional response in hypoxia. Most impor-
tantly, these data suggest that p53-dependent apoptosis in 
response to hypoxia could still play a role in tumor suppression.
We focused on genes that have been linked with apoptosis 
(INPP5D, PHLDA3, sulfatase 2 [SULF2], B cell translocation gene 2 
[BTG2], cytoplasmic FMR1-interacting protein 2 [CYFIP2]) 
or tumor suppression (KANK3) (23, 28–31). Using quantita-
tive PCR (qPCR), we validated these genes as being hypoxia 
inducible in a p53-dependent manner in the HCT116 isogenic 
cell lines (p53+/+ and p53–/–) (Figure 2A). We also demonstrated 
that, in addition to the DBD, the transactivation domains of p53 
(p5322, p5323, p5353, p5354) were required to induce these targets 
in hypoxia (Supplemental Figure 2, A and B). p53 response ele-
ments (REs) have been identified in PHLDA3, SULF2, CYFIP2, 
and KANK3, so we used ChIP to determine whether p53 was 
enriched at these sites in hypoxia (Figure 2B and refs. 32–34). 
In each case, there was a clear accumulation of p53 at the REs in 
hypoxia, demonstrating direct transactivation of these targets in 
response to hypoxia as well as the DNA-damaging stresses pre-
viously reported. In addition, we confirmed that PHLDA3 and 
SULF2 proteins were induced in hypoxia in a p53-dependent 
manner, again using p53+/+ and p53–/– HCT116 cells or RKO cells 
treated with siRNA to p53 (Supplemental Figure 2, C–E). We 
also observed a hypoxic induction of both PHLDA3 mRNA and 
PHLDA3 protein in a human nontumor lung fibroblast cell line, 
WI38, suggesting that this regulation is not restricted to tumor 
cells (Supplemental Figure 2, F and G).
Previous reports suggest an interaction between p53 and 
HIF-1α (35). We have determined that PHLDA3 and INPP5D were 
induced in response to <0.1% O2 when both p53 and HIF-1 were 
induced but not in response to 2% O2 when only HIF-1 was sta-
bilized (Supplemental Figure 3, A–C). This was further verified in 
HIF1A+/+ and HIF1A–/– RKO cells, in which PHLDA3 and INPP5D 
were highly induced by hypoxia irrespective of HIF-1α status, as 
opposed to the HIF-1α target, GLUT1, which was not induced in 
the HIF1A–/– cell line (Supplemental Figure 3, D–G). This dem-
onstrates that HIF-1α does not contribute to the induction of the 
hypoxia-induced p53-dependent genes described.
Hypoxia-induced p53 specifically transactivates the INPP5D 
transcript associated with stem cells. INPP5D has been recently 
(e.g., TIGAR, GLS2, or ULK1) appear to be crucial in tumor sup-
pression (24–26). Recently, using genetically engineered mouse 
knockin models in the transactivation domains of p53, Brady 
et al. demonstrated that the genes critical for the acute DDR 
of p53 and for tumor suppression differ. Brady et al. identified 
14, mostly novel, p53 targets required for p53-mediated tumor 
suppression (23). The induction of these genes was found to be 
dependent on both of the transactivation domains of p53 and an 
intact DBD. More recently, additional mouse models showed 
that acetylation of p53 at specific lysine residues K117/K161/
K162 (corresponding to K120/K164 in humans) in the DBD are 
essential for DNA damage–induced apoptosis but are dispens-
able for p53-dependent tumor suppression (24). These studies 
have led to the conclusion that p53-induced apoptosis is not 
required for tumor suppression.
In this study, we investigated the p53-mediated transcrip-
tional response to hypoxia and specifically the mechanism of 
p53-induced apoptosis in these conditions. Hypoxia-induced 
p53-dependent apoptosis was reliant on DNA binding (R175) but 
not acetylation in the DBD (K120, K164). We show that a group 
of 6 validated hypoxia-inducible p53 target genes was found to 
predict p53 status in samples from patients with cancer; in addi-
tion, we show that when these genes were underexpressed they 
correlated with poor clinical outcome in two independent anal-
yses of large human breast cancer cohorts, with a total of more 
than 3,000 patients, and other human cancers. Two of the p53 
targets induced in hypoxia, pleckstrin domain–containing A3 
(PHLDA3) and inositol polyphosphate-5-phosphatase (INPP5D, 
which encodes SHIP-1), were found to induce apoptosis through 
inhibition of AKT signaling. We show that by mimicking the 
function of WT p53 in hypoxia using a pharmacological inhib-
itor of AKT we can increase apoptosis specifically in hypoxic 
areas of tumors with nonfunctional p53 but not in tumors with 
WT p53. Furthermore, increased apoptosis in the hypoxic frac-
tion induced through AKT inhibition correlated with significant 
radiosensitization in an esophageal tumor model.
Results
Hypoxia-induced p53 transactivates specific target genes. Using 
hypoxia-inducible p53 constructs in p53-null H1299 cells, we 
investigated the role of DNA binding and acetylation of p53 in 
hypoxia-induced apoptosis (18). Mutation of the acetylation 
sites in the p53 DBD (K120R, K164R, K120R/K164R) had no 
significant effect on the level of hypoxia-induced apoptosis, in 
contrast to a structural mutation of the DBD (R175H), which 
prevented DNA binding and abrogated apoptosis entirely (Fig-
ure 1, A and B). However, in agreement with previous reports, 
acetylation at K120 and/or K164 was critical for p53-dependent 
apoptosis in response to camptothecin-induced DNA damage 
(Supplemental Figure 1, A and B) (27). These data immedi-
ately suggested that the mechanism of hypoxia-induced p53- 
dependent apoptosis differs from the response to DNA-damag-
ing agents (24, 27). Using the same inducible system, we carried 
out an expression array to compare the transcriptional response 
to WT p53 and p53R175H in hypoxia. As expected, the well- 
characterized p53 proapoptotic targets, including BAX, PUMA, 
NOXA, or BID, were not upregulated by p53 in response to 
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was conserved between species (chr2:233,139,693–233,139,712 
of hg38 human genome assembly) (Figure 2D). Using ChIP, we 
verified that this sequence is a bona fide p53 RE and that occu-
pancy of this region by p53 was enhanced in hypoxia to a similar 
level as that seen for PHLDA3, SULF2, CYFIP2, or KANK3 (Fig-
ure 2E). The closely related member of the INPP5D gene family, 
INPPL1, did not increase in hypoxia (Supplemental Figure 4C). 
The expression of short INPP5D has been previously character-
ized mainly in mouse embryonic stem cells, although the mech-
anism of induction is unclear (37). We found that expression of 
this particular transcript was increased in response to hypoxia, 
not only in cancer cells but also in embryonic stem cells (Supple-
mental Figure 4D). This correlated with an accumulation of p53 
protein and induction of apoptosis in the embryonic stem cells in 
hypoxia (Supplemental Figure 4E). These data together demon-
described as a p53 target gene with 2 p53 REs in intron 9 (36). We 
carried out ChIP analysis using both these REs and found that 
one of them was moderately enriched for p53 binding in hypoxia 
(Supplemental Figure 4A). To investigate further and as multi-
ple INPP5D transcript variants exist, we asked which transcript 
was induced in hypoxia (37). By carrying out PCR with specific 
primers, we determined that RKO and HCT116 cells expressed 
only the short INPP5D transcript (U50040), which was fur-
ther induced by hypoxia (Figure 2C and Supplemental Figure 
4B). This particular transcript is transcribed from an internal 
promoter in intron 5 of the full-length INPP5D gene (37). We 
aligned this region with the corresponding mouse and rat loci of 
the INPP5D gene and found a region of conserved similarity in 
the sequence directly preceding the cDNA of the short INPP5D. 
Within this region, we identified a novel putative p53 RE, which 
Figure 1. Hypoxia-induced p53-dependent apoptosis is associated with the expression of specific genes. (A and B) Apoptosis in H1299 cells expressing 
either WT p53 (p53) or the mutants (K120R, K164R, K120/164R, R175H) from the 5xHRE promoter and exposed to 24 hours of hypoxia (Hyp) or normoxia 
(Norm) detected by PARP cleavage or morphologically, respectively. For Western blotting, the lanes were run on the same gel but were noncontiguous. The 
bar graph shows mean ± SEM (combined n = 3, 2-way ANOVA test [****P < 0.0001]). (C) Microarray gene expression analysis in H1299 cells transfected 
with either 5xHRE-p53 or 5xHRE-p53R175H and exposed to 16 hours of hypoxia. Heat map showing the top candidate genes induced by hypoxia in a p53- 
dependent manner. Well-characterized proapoptotic p53 targets are shown in the bottom 6 rows. Fold change ratios of gene expression for 5xHRE-
p53/5xHRE-p53R175H samples are shown in red for upregulated and blue for downregulated genes. Columns numbered 1 to 3 represent technical replicates 
of hypoxic samples. (D) qPCR testing of the hypoxic regulation of p53 target genes identified as being essential to its tumor-suppressive role by Brady  
et al. (22) in H1299 cells transfected with 5xHRE-p53 and exposed to 24 hours of hypoxia. The bar graph shows mean ± SEM (combined n = 3, 2-way ANOVA 
test [P < 0.0001] followed by 2-tailed Student’s t test [***P < 0.001; ****P < 0.0001].
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strate the significance of this result, we defined an equally sized 
control group of known p53 target genes that are not induced by 
hypoxia (Figure 1C) but have well-characterized roles in DNA 
damage–induced apoptosis: PUMA, BID, PERP, BAX, PIG3, and 
NOXA (10). Although the analysis of this control group did iden-
tify 3 data sets where the underexpression of these genes was 
associated with TP53 mutation (Supplemental Figure 5B), this 
was not a statistically significant enrichment (hypergeometric 
test, P = 0.599). This led us to conclude that the p53-dependent 
genes identified here in vitro as hypoxia inducible are likely to be 
regulated by p53 in vivo. Moreover, the hypoxia-inducible group 
of genes (PHLDA3, INPP5D, SULF2, BTG2, CYFIP2, and KANK3) 
was a better predictor of p53 status than a control group of 
strate that in response to hypoxia p53 induces expression of a 
specific short INPP5D transcript, the expression of which was 
previously associated predominantly with embryonic stem cells.
The collective expression of hypoxic p53 targets is regulated in 
cancers and correlates with patient prognosis. To investigate the 
relevance of the p53 target genes induced in response to hypoxia 
in cancer patients, we analyzed all available Oncomine data 
sets using our validated p53 hypoxic targets: PHLDA3, INPP5D, 
SULF2, BTG2, CYFIP2, and KANK3. The underexpression of this 
group of genes correlated significantly with TP53 mutation in 9 
studies (Supplemental Figure 5A); this represents a statistically 
significant enrichment with respect to association with any other 
mutation (hypergeometric test, P = 0.0279). To further demon-
Figure 2. Transcriptional activity of p53 is required to induce expression of a specific group of genes in hypoxia. (A) Validation of p53 targets by 
qPCR in p53+/+ and p53–/– HCT116 cells exposed to hypoxia. The bar graph shows mean ± SEM (combined n = 3, 2-way ANOVA test [*P < 0.05; **P < 0.01; 
***P < 0.001]). (B) qPCR for p53 ChIP in HCT116 cells exposed to 8 hours of normoxia or hypoxia for the genes indicated. The bar graph shows mean 
± SEM (combined n = 3, 2-way ANOVA test [P < 0.0001] followed by 2-tailed Student’s t test [*P < 0.05]). (C) PCR for the INPP5D transcripts using a 
combination of primers (marked as arrows in Supplemental Figure 2A) specifically detecting the short INPP5D transcript (F4+R4 or F4+R1), all INPP5D 
transcripts (F1+R1), or the full-length INPP5D transcript (F4a+R4 or F5+R4) on the cDNA from HCT116 or RKO cells exposed to 16 hours of hypoxia. 
THP-1 cDNA was used as a control for the expression of the full-length INPP5D. RPS29 is shown as a control gene. (D) Alignment of the putative p53 
RE of the short INPP5D in human, mouse, and rat. A consensus p53 RE is shown below the alignment. (E) qPCR for p53 ChIP at the putative p53 RE 
in the short INPP5D promoter in HCT116 cells exposed to 8 hours of normoxia or hypoxia. The bar graph shows mean ± SEM (combined n = 3, 2-tailed 
Student’s t test [*P < 0.05]).
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clinical outcome. When we again compared the control group of 
well-characterized p53 proapoptotic genes (PUMA, BID, PERP, 
BAX, PIG3, and NOXA), we found that only 4 data sets were sig-
nificantly associated with their collective expression; notably, in 
all 4 cases, it was the overexpression, rather than underexpres-
sion, of these genes that correlated with poor clinical outcome 
(Supplemental Figure 5C).
Next, we carried out independent meta-analyses on pub-
lically available, large, and well-characterized breast cancer 
patient cohorts. The first analysis was performed on 6 curated 
retrospective breast cancer data sets deposited in the Gene 
Expression Omnibus repository, in which clinical information 
was published for a total of 1,050 cases (GSE6532KI, GSE-
6532GUY, GSE6532OXF, GSE9195, GSE1456, and GSE2034). 
Tests for heterogeneity showed that the 6 data sets could be 
merged safely (P = 0.785). The p53 status of these samples is 
well-known p53 proapoptotic targets (PUMA, BID, PERP, BAX, 
PIG3, and NOXA) induced in response to DNA damage.
We then tested whether collective expression of the group of 
genes induced by p53 under hypoxia (PHLDA3, INPP5D, SULF2, 
BTG2, CYFIP2, and KANK3) was associated with any consistent 
clinical outcome in patients with cancer. An Oncomine search 
of all the available data for patients with cancer identified 17 
data sets in which underexpression of this group of genes was 
significantly associated with a poor clinical outcome in patients 
with breast, lung, gastric, melanoma, sarcoma, ovarian, and col-
orectal cancers (Figure 3A). Conversely, no studies were found 
in which overexpression of this group of genes correlated with 
poor clinical outcome. The expression of these genes tested 
individually in Oncomine did not show any consistent pattern 
of their expression correlating with patient prognosis, suggest-
ing that their concomitant regulation is the relevant factor for 
Figure 3. Underexpression of hypoxia-inducible proapoptotic p53 targets 
predicts p53 status and correlates with poor clinical outcome in patients with 
cancer. (A) Heat map showing a grouped expression of validated hypoxia- 
inducible proapoptotic p53 targets (PHLDA3, INPP5D, SULF2, BTG2, CYFIP2, 
and KANK3) correlated with a clinical outcome in patients with cancer. Rows 
represent single data sets associated with the tested group of genes in the 
Oncomine database (described in the Supplemental Methods), with the cancer 
types indicated on the left and clinical outcome on the right. A significant fold 
change in gene expression (P ≤ 0.01) is shown in purple. Not significant and not 
tested (nt) expression of genes are shown in white and gray, respectively. rec., 
recurrence; met., metastatic. (B) Box plots showing the summary expression 
distribution for the p53-dependent hypoxia-inducible group of genes from A in 
p53 WT and mutant (mut) breast cancer samples from the METABRIC breast 
cancer patient cohort (32). Red dots show the scores for individual patients, jit-
tered horizontally. The bottom and top of each box represent the first and third 
quartiles, respectively. The line and band inside each box indicate median sum-
mary expression. The whiskers of the box indicate 1.5 times interquartile range. 
The mean expression of these genes was considered as the summary expres-
sion. Wilcoxon test and t test results are provided on the plot. (C) A Kaplan-
Meier plot showing meta-analysis for the overall survival (OS) and expression 
of hypoxia-inducible p53-dependent genes performed on the METABRIC breast 
cancer patient cohort. The total number of patients at risk at time points 0 to 12 
years is shown below the x axis. HR, hazard ratio.
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unknown, and so we used a recently described p53 gene signa-
ture to determine the likely p53 status and then asked whether 
our group of genes was expressed in a p53-dependent manner 
(38). Using this approach, we found that our p53-dependent 
hypoxia-inducible group of genes was expressed at a significantly 
lower level in p53-mutated samples (P < 1 × 10–7; Supplemental 
Figure 6A). This provided independent validation for the conclu-
sion reached through earlier Oncomine analysis, showing that 
the group of hypoxic p53 targets is significantly and consistently 
associated with p53 mutation status in vivo. Next, we found that 
underexpression of hypoxic p53 targets correlated with a lower 
recurrence-free survival, with a summary effect hazard ratio 
of 0.63 (95% confidence limits of 0.42 and 0.96) in the breast 
cancer data sets (Supplemental Figure 6B). We then carried out 
a similar meta-analysis on the data from the recently published 
METABRIC study, which consists of a large cohort of patients 
with breast cancer, for a total of 2,000 human cancer samples 
(39). The p53 status in a subset of these samples was known, and 
we confirmed once more in an independent data set that lower 
expression of our hypoxia-inducible p53-dependent genes sig-
nificantly correlated with p53 mutation status (Figure 3B). As 
expected, breast cancer subtypes associated with high rates of 
p53 mutations, such as basal-like cancers (40), showed the low-
est expression of the group of genes (Supplemental Figure 7). 
Figure 4. p53 targets PHLDA3 and INPP5D mediate apoptosis in hypoxia. (A and B) Apoptosis detected morphologically or by Western blotting for 
PARP cleavage, respectively, in H1299 cells transfected with 5xHRE-PHLDA3 and exposed to 24 hours of hypoxia. The bar graph shows mean ± SEM 
(n = 3; 2-tailed Student’s t test [**P < 0.01]). For Western blotting, the lanes were run on the same gel but were noncontiguous. (C and D) Apoptosis 
detected morphologically or by Western blotting for cleaved PARP or caspase-3 (cl. Casp3) in RKO cells treated with nonspecific (Scr), PHLDA3, or p53 
siRNA and exposed to 18 hours of hypoxia or normoxia. The bar graph shows mean ± SEM (n = 3, 2-way ANOVA test [P < 0.0001] followed by 2-tailed 
Student’s t test [***P < 0.01]). (E and F) Apoptosis detected in RKO cells treated with nonspecific, PHLDA3, INPP5D, or p53 siRNA as indicated and 
exposed to 14 hours of hypoxia or normoxia. The bar graphs show mean ± SEM (n = 3, 2-way ANOVA tests [P < 0.0001 for both graphs] followed by 
2-tailed Student’s t test [**P < 0.01; ****P < 0.0001]). (G) Apoptosis detected morphologically in RKO cells treated with nonspecific, p53, or PHLDA3 
siRNA and exposed to 14 hours of hypoxia or normoxia in the presence or absence of INPP5D/SHIP-1 inhibitor 3AC. The bar graph shows mean ± SEM 
(n = 3, 2-way ANOVA test [P < 0.0001] followed by 2-tailed Student’s t test [*P < 0.05; **P < 0.01]).
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This analysis also highlighted that these genes are expressed at 
higher levels in tumor tissue compared with that in normal tis-
sue. Again, the lower expression of this group of genes correlated 
with poor patient outcome, as measured by overall survival over 
12 years in the entire METABRIC cohort (Figure 3C).
PHLDA3 and INPP5D mediate p53-dependent apoptosis in 
hypoxia. Since the collective expression of the p53 target genes 
inducible in response to hypoxia significantly correlated with the 
clinical outcome of patients with cancer, we went on to investi-
gate the function of these genes in hypoxia. Interestingly, two 
of the most highly induced p53 targets in hypoxia, PHLDA3 
and INPP5D, were both previously shown to induce apoptosis 
through negative regulation of AKT signaling (32, 37, 41). This 
led us to hypothesize that p53 can induce apoptosis in hypoxia 
via inhibition of AKT and that this is reliant on the coordi-
nated functions of more than one target gene. We expressed a 
5xHRE-PHLDA3 construct in p53-null H1299 cells and exposed 
them to hypoxia. As expected, PHLDA3 localized to the plasma 
membrane and significantly increased the percentage of apop-
tosis (Figure 4, A and B, and Supplemental Figure 8A). siRNA- 
mediated knockdown of PHLDA3 significantly compromised 
hypoxia-induced apoptosis in RKO cells, although not to the same 
Figure 5. Hypoxia-induced activation of AKT is attenuated by p53/PHLDA3/SHIP-1 signaling. (A–C) Western blotting comparing AKT-S473 phosphorylation 
in H1299, HCT116 (p53–/–), and WT HCT116 cells, respectively, exposed to hypoxia for the times indicated. (D) Western blotting for antibodies indicated in RKO 
cells transfected with either p53 or PHLDA3 siRNA and exposed to 8 hours of hypoxia. (E) Representative images of immunofluorescent costaining with 
anti-PHLDA3 (green) and anti–pAKT-S473 (red) antibodies in H1299 cells transfected with 5xHRE-PHLDA3 or control and exposed to hypoxia for 12 hours. 
Scale bar: 10 μm. (F) Hypoxic time course for the mean intensity of pAKT-S473 fluorescence per cell in control or PHLDA3-expressing cells from E. The plot 
shows mean ± SEM (n = 3, 2-way ANOVA test [**P < 0.01]). (G) Western blotting in HCT116 cells exposed to 18 hours of normoxia or hypoxia in the presence 
or absence of SHIP-1 inhibitor, 3AC. (H) Western blotting in RKO cells exposed to 14 hours of normoxia or hypoxia in the presence or absence of 3AC.
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combined with a nontargeting siRNA (Figure 4G). In summary, 
these data confirm that both p53 targets, PHLDA3 and short 
INPP5D, contribute to p53-dependent apoptosis in hypoxia.
Hypoxia-induced activation of AKT is sustained in the absence 
of p53 function. In contrast to our hypothesis that p53 induces 
apoptosis in hypoxia by inhibiting AKT signaling, previous 
studies have demonstrated that hypoxia activates AKT (43, 44). 
We also found that hypoxia potently induced phosphorylation 
of AKT at S473 (pAKT-S473). However, we noted that this acti-
vation of AKT was only sustained in p53-null or p53 mutant 
cells (HCT116 p53–/–, H1299, OE21, or PSN1) compared with 
p53 WT cells (RKO or HCT116) (Figure 5, A–C, and Supplemen-
tal Figure 8, H–J). These data support our hypothesis that p53 
may be negatively regulating AKT activation in hypoxia. In fur-
ther support of this, siRNA-mediated depletion of endogenous 
PHLDA3 or p53 in RKO cells increased pAKT-S473 in hypoxia 
(Figure 5D). We also found that overexpression of PHLDA3 in 
H1299 cells significantly reduced hypoxic activation of AKT, 
as judged by the fluorescent intensity of pAKT-S473 staining 
in PHLDA3-expressing cells compared with that in PHLDA3- 
negative cells (Figure 5, E and F). In addition, inhibition of 
extent as p53 siRNA knockdown (Figure 4, C and D). Likewise, 
siRNA knockdown of short INPP5D also significantly impaired 
hypoxia-induced apoptosis in these cells (Figure 4E). How-
ever, when both p53 targets, PHLDA3 and short INPP5D, were 
knocked down, the decrease in hypoxia-induced apoptosis was 
more profound than the levels of apoptosis observed with single 
knockdown of PHLDA3 or INPP5D alone and similar to the lev-
els of apoptosis induced by p53-targeted siRNA, suggesting that 
these targets synergize in order to mediate apoptosis (Figure 4F). 
The efficiency of PHLDA3, p53, and INPP5D knockdown is 
quantified in Supplemental Figure 8, B–D. The proapoptotic 
function of the SHIP-1 protein (encoded by INPP5D) is reliant on 
its phosphatase domain, which is included in the short INPP5D 
transcript (37). Given that the phosphatase activity of SHIP-1 
is essential for the induction of apoptosis, we investigated the 
SHIP-1–specific phosphatase domain inhibitor, 3AC (42). The 
use of 3AC decreased hypoxia-induced apoptosis in a dose- 
dependent manner in a number of p53 WT cell lines (Supplemen-
tal Figure 8, E–G). In addition, when the SHIP-1 inhibitor, 3AC, 
was combined with PHLDA3 siRNA knockdown in RKO cells, we 
found that the combination reduced apoptosis further than 3AC 
Figure 6. Pharmacological inhibition of AKT sensitizes p53-deficient hypoxic tumor cells. (A–C) Apoptosis detected by PARP cleavage in OE21, 
H1299, and HCT116 cells, respectively, exposed to 24 hours of hypoxia or normoxia in the presence of MK-2206 or DMSO. For Western blotting in C, 
the lanes were run on the same gel but were noncontiguous. (D–F) Apoptosis detected morphologically in OE21, H1299, and HCT116 cells, respec-
tively, exposed to 24 hours of hypoxia or normoxia in the presence of MK-2206 or DMSO. (G–I) Colony survival assay in OE21, H1299, and HCT116 cells, 
respectively, exposed to 24 hours of hypoxia or normoxia in the presence of MK-2206 or DMSO. All the bar graphs show mean ± SEM (n = 3; 2-tailed 
Student’s t test [*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001]).
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Figure 7. Pharmacological inhibition of AKT induces apoptosis in hypoxic regions of p53-deficient tumors and increases radiosensitivity. (A) 
MK-2206 treatment in OE21 xenografts. Mice were given 60 mg/kg MK-2206 or vehicle alone on 3 alternate days, and, 24 hours after the last dose, 
tumors were collected for analysis. (B) Representative images of colocalization of pAKT-S473 with hypoxic areas of OE21 xenografts stained with 
pimonidazole antibody (PIMO). Scale bar: 50 μm. (C) Representative images of colocalization of cleaved caspase-3 with hypoxic areas of OE21 
xenografts stained with CAIX antibody. Scale bar: 50 μm. (D) Plots showing the percentage of apoptosis in either normoxic or hypoxic regions from 
all the regions analyzed. The bar represents the mean ± SEM from 3 animals per each group (2-tailed Student’s t test [****P < 0.0001]). (E) OE21 
xenografts were grown in mice as in A, and a day after the last dose of MK-2206 or vehicle, tumors were treated with a single dose of IR (10 Gy). 
Tumor volumes were measured for 5 (vehicle), 5 (vehicle+IR), 6 (MK-2206), and 6 (MK-2206+IR) mice per each group, and mean ± SEM is shown. (F) 
A Kaplan-Meier plot showing the survival probability of mice in each treatment group (log-rank [Mantel-Cox] test with P < 0.0001 shown for all the 
curves compared together; comparisons of 2 single curves at the time were significant [P < 0.05] for all the combinations except the Vehicle+IR group 
versus MK-2206 group).
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A decrease in the hypoxic fraction of solid tumors through 
increased apoptosis would be predicted to increase radiosensitivity. 
To test this, we chose to use an esophageal cancer model, due 
to the high rates of p53 mutation and the significant correlation 
between p53 status and patient prognosis in this cancer (45). OE21 
xenografts were grown, and the mice were treated with either 
60 mg/kg MK-2206 or vehicle on 3 alternate days, followed by a 
single dose of 10 Gy irradiation (IR) (Figure 7E). MK-2206 or IR 
alone delayed tumor growth from 100 to 250 mm3 for approxi-
mately 4 days in comparison to that in the vehicle-treated control 
group. However, the combined MK-2206 and IR treatment had a 
profound effect in delaying tumor growth from 100 to 250 mm3 for 
12 days when compared with vehicle treatment or for 8 days when 
compared with either treatment with IR or MK-2206 alone (Fig-
ure 7E). This was reflected by the significantly prolonged median 
survival of mice treated with the combined therapy in comparison 
to either treatment alone (Figure 7F). These data confirmed our 
hypothesis that the radiosensitizing potential of AKT inhibitors 
could in part be mediated through a decrease in the hypoxic frac-
tion of tumors that have lost functional p53 (Figure 8).
Discussion
Our study demonstrates that p53 is transactivation competent in 
response to replication stress induced by hypoxia (<0.1% O2). A 
validated subset of the genes identified was significantly and con-
sistently associated with p53 mutation status and patient progno-
sis in several clinical cohorts of patients with cancer, which both 
confirms the p53 dependency and highlights the importance of 
the hypoxia-induced p53 response. Two of the genes identified 
(PHLDA3 and INPP5D) both inhibit AKT signaling and promote 
apoptosis in hypoxia. This suggests that tumors that have lost p53 
function may be more sensitive to AKT inhibition, due to restora-
tion of proapoptotic signaling in hypoxia (Figure 8). In support of 
this, we demonstrate increased apoptosis in hypoxia in response 
to an AKT inhibitor (MK-2206) in the absence of functional p53 
both in vitro and in OE21 and PSN1 tumors in vivo. Most signifi-
cantly, we found that esophageal p53-deficient tumors that had 
increased apoptosis specifically in hypoxic areas also showed an 
increased response to radiotherapy.
Recently a number of mouse models have been used to deter-
mine the mechanism of p53-mediated tumor suppression. These 
include the mutation of key residues such as K117/K161/K162 
SHIP-1 with 3AC increased pAKT-S473 in hypoxia in HCT116 
and RKO cells (Figure 5, G and H).
Inhibition of AKT increases apoptosis in p53-deficient hypoxic 
cells. Our data suggest that one of the functions of hypoxia- 
induced p53 is to restrict AKT signaling and drive cells into apop-
tosis. We asked whether the use of pharmacological inhibitors of 
AKT could be an effective approach to target hypoxic tumor cells. 
A panel of cells lines, expressing mutant p53 or not, were exposed 
to the allosteric AKT inhibitor MK-2206, and apoptosis assays 
were carried out. We observed a significant induction of apopto-
sis in cells (OE21, H1299, PSN1) treated with MK-2206 in com-
bination with hypoxia but not with MK-2206 alone (Figure 6, A, 
B, D, and E, and Supplemental Figure 9, A–D). As expected, low 
levels of apoptosis were observed in these cells (p53 mutant/null) 
in response to hypoxia alone. This was also reflected in a differ-
ence in overall survival, as measured by clonogenic assay (Figure 
6, G and H). In contrast, treatment with MK-2206 did not further 
increase hypoxia-induced apoptosis or affect overall survival in 
HCT116 cells expressing WT p53 (Figure 6, C, F, and I) or H1299 
cells transfected with the HRE-p53 construct (Supplemental Fig-
ure 9, C and D). These data demonstrate that p53 inhibits AKT sig-
naling in hypoxia and hypoxic cells that have lost p53 function are 
more sensitive to inhibition of AKT.
Inhibition of AKT increases apoptosis in hypoxic regions of p53- 
deficient tumors and increases radiosensitivity. To validate these 
findings in vivo, we grew OE21 (p53p.S90fs31X, c.269C>T, c.270delC), PSN1 
(p53K132Q ), and HCT116 (p53WT) cells as tumor xenografts and treated 
them with either MK-2206 or vehicle alone (Figure 7A; Supplemen-
tal Figure 10, A and B; Supplemental Figure 11A; and Supplemental 
Figure 12A). As expected, pAKT-S473 was induced in the pimoni-
dazole-positive hypoxic regions of these tumors, and this was effi-
ciently inhibited by treatment with MK-2206, as judged by immuno-
fluorescent staining or Western blotting of harvested tumors (Figure 
7B, Supplemental Figure 10, and Supplemental Figure 11B). Most 
importantly, we found that AKT inhibition significantly increased 
apoptosis in the hypoxic areas of the p53-deficient tumors (Figure 7, 
C and D, and Supplemental Figure 11, C and D) but not in those of the 
p53 WT tumors (Supplemental Figure 12, B and C), as determined by 
costaining of cleaved caspase-3 and CAIX. These data support our 
hypothesis that the mechanism of p53-dependent hypoxia-induced 
apoptosis includes AKT inhibition and that this can be exploited in 
vivo through pharmacological inhibitors.
Figure 8. AKT inhibition radiosensitizes p53-deficient hypoxic 
tumors. (A) In response to hypoxia, p53 induces specific target 
genes, the role of which includes the induction of apoptosis. One 
of the mechanisms of apoptosis induction by p53 in hypoxia is 
through the inhibition of AKT signaling via PHLDA3 and INPP5D. 
In the p53-deficient tumors, the expression of PHLDA3 and 
INPP5D is abrogated, which facilitates activation of AKT and 
consequently inhibition of apoptosis. (B) Targeting p53-deficient 
tumors with PI3K/AKT inhibitors (PI3K/AKTi) is a promising 
strategy to restore the signaling of p53 in the hypoxic cells and 
eliminate therapy-resistant tumor fractions.
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PI3K/AKT inhibitors when combined with radiotherapy (53–57). 
AKT inhibition has also been demonstrated to improve radiosen-
sitivity through normalization of the tumor vasculature (58). Our 
study, for the first time to our knowledge, demonstrates that inhi-
bition of AKT in hypoxia may have a different effect with respect 
to p53 status and suggests that patients with cancer stratified for 
high tumor hypoxia and loss of p53 may get the most benefit from 
combined radiotherapy and AKT inhibition. The group of 6 genes 
identified and validated in this study offers a promising candi-
date biomarker to identify patients who could benefit from this 
approach. In summary, by fully characterizing the p53 transcrip-
tional response to hypoxia, we have identified a stress-specific 
proapoptotic response, which could be exploited therapeutically 
and is relevant to patient prognosis.
Methods
Cell lines and plasmid transfection. RKO and HCT116 (colorectal car-
cinoma), H1299 (non-small-cell lung carcinoma), OE21 (esophageal 
squamous carcinoma), PSN1 (pancreatic adenocarcinoma), WI38 
(lung fibroblasts), CCE (mouse embryonic stem cells), and THP-1 
(acute monocytic leukemia) cell lines and plasmid transfection proce-
dures are described in the Supplemental Methods.
Hypoxia/drug treatment. A Bactron chamber (Shel Lab) was used 
for studies at <0.1% O2 and an in vivo 400 chamber (Baker Ruskinn) 
was used for 2% O2. All hypoxic treatments were performed at <0.1% 
O2 unless indicated otherwise. The following drug concentrations 
were used: 25 μM etoposide (Sigma-Aldrich); 1 μM MK-2206 (Selleck 
Chemicals); and 0.5-1 μM 3AC (Calbiochem).
Immunoblotting. Both adherent and detached cells were col-
lected and lysed in SDS lysis buffer (10 mM Tris-Cl, pH 7.5, 0.1 mM 
EDTA, 0.1 mM EGTA, 0.5% SDS, 0.1 mM β-mercaptoethanol, 
protease/phosphatase inhibitors). The following antibodies were 
used: p53 (DO-I, Santa Cruz), p53 (C-19, Santa Cruz), β-actin 
(AC-15, Santa Cruz), p53 (1C12, Cell Signaling Technology), p53-S15 
(9284, Cell Signaling Technology), PARP (9542, Cell Signaling 
Technology), cleaved caspase-3 (9661, Cell Signaling Technology), 
pAKT-S473 (4060, Cell Signaling Technology), AKT (4691, Cell Sig-
naling Technology), PHLDA3 (ab22822, Abcam), γH2AX (JBW301, 
Upstate-Millipore), H2AX (DR1016, Calbiochem), HIF-1α (610958, 
BD Biosciences), and GAPDH (6C5, Novus Biologicals). The Odyssey 
infrared system (LI-COR) was used to image Western blots.
siRNA knockdown. RKO cells were transfected using DharmaFECT 
1 reagent (Thermo Fisher Scientific). siRNA duplexes were used at 
50 nM, and 24 hours after knockdown, cells were replated to be used in 
assays up to 72 hours after transfection. siRNA sequences are listed in 
the Supplemental Methods.
Apoptosis detection. Apoptosis by nuclear morphology was assessed 
in combined adherent and detached cells fixed in 4% paraformaldehyde. 
Apoptosis was measured as the percentage of cells with fragmented 
DNA per 10 fields in every treatment. Graphs show mean values ± SEM 
from 3 independent experiments.
Colony survival assay. H1299, OE21, and HCT116 cells were 
treated either with DMSO or 1 μM MK-2206 and exposed to 24 hours 
of hypoxia or normoxia. Subsequently, all cells were placed in a nor-
moxic incubator and left for 9 days to form colonies, which were visu-
alized by crystal violet staining. Graphs show mean values ± SEM from 
3 independent experiments.
(corresponding to K120/K164 in humans) or coordinated knock-
out of genes, such as PUMA, NOXA, and p21 (24, 25). These studies 
demonstrate that DNA damage–induced p53-dependent apoptosis 
mediated by the classic target genes is not required for tumor sup-
pression. This is supported by our finding that the levels of PUMA, 
BID, PERP, BAX, PIG3, and NOXA as a group do not predict patient 
outcome in clinical samples. Our study demonstrates that the hypox-
ia-induced transcriptional response of p53 uses alternative proap-
optotic pathways, which substantially differ from those induced by 
genotoxic stress. Hypoxia-induced p53-mediated apoptosis could 
therefore be a crucial component of tumor suppression. In support 
of this hypothesis, some of the hypoxia-inducible p53 targets, such as 
PHLDA3 and KANK3, have already been linked with p53-mediated 
tumor suppression (23, 46). By carrying out thorough and indepen-
dent analyses of large clinical cohorts of breast and other cancers, 
we found that poor patient prognosis and progression of disease are 
significantly and consistently associated with diminished expression 
of the hypoxia-inducible p53-dependent group of genes, suggesting 
that their function is lost in aggressive cancers.
Previous studies have demonstrated that hypoxia-induced p53 
is proapoptotic and suggest that this is the primary role for p53 in 
hypoxia (11, 18, 21). The relevance of apoptosis was further sup-
ported by our finding that a number of the hypoxia-induced targets 
identified here had previously been described as proapoptotic, as 
opposed to having roles in alternative p53-mediated responses. 
However, it is probable that hypoxia-induced p53 has additional 
functions, i.e., other than driving cells into apoptosis. For exam-
ple, it is well known that cancer cells have increased glycolytic flux 
and suppressed oxidative phosphorylation, even in the presence 
of oxygen, and recently, the tumor-suppressive function of p53 
was attributed to inhibition of glycolytic flux through induction 
of TIGAR (24). Interestingly, in hypoxia, TIGAR has been showed 
to protect from cell death via regulation of mitochondrial reactive 
oxygen species (47). Therefore, it would be interesting to investi-
gate whether any of the targets identified in this study have roles in 
regulating cell metabolism under hypoxic conditions and whether 
this could in turn play a role in tumor suppression.
INPP5D, which encodes SHIP-1, specifically converts 
phosphatidylinositol-(3,4,5)-trisphosphate [PI(3,4,5)P3] to PI(3,4)
P2 and therefore depletes the pool of PI3K-generated PI(3,4,5)P3 
at the plasma membrane, resulting in impaired AKT activation 
(41). However, AKT can be also recruited to the plasma mem-
brane by PI(3,4)P2 as well as PI(3,4,5)P3. Therefore, it is significant 
that hypoxia-induced p53 also transactivates PHLDA3, which, 
through its pleckstrin homology domain, can bind both PI(3,4,5)
P3 and PI(3,4)P2, leading to efficient inactivation of AKT (32, 48). 
This confirms that one of the principle roles of hypoxia-induced 
p53 is to restrict protumorigenic PI3K/AKT signaling.
AKT activation in hypoxic regions of breast tumors has been 
linked with poor patient prognosis (49). One of the known func-
tions of AKT is to block apoptosis through phosphorylation of 
multiple targets, for example, caspase-3/9 or BAD (50). There-
fore, inhibition of AKT is a promising strategy to eliminate cancer 
cells via reactivation of apoptosis. Many PI3K/AKT inhibitors are 
currently undergoing clinical trials, yet surprisingly, the available 
clinical data show little evidence for single-agent activity (51, 52). 
However, several studies describe promising antitumor activity of 
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Animals were randomized, and treatments were started when tumor 
volumes reached 100 mm3 (volume = height × depth × width × π/6). 
Animal groups received either vehicle (25% cyclodextrin) or 60 mg/kg 
MK-2206 s.c. (PSN1 and HCT116) or orally (OE21) on 3 alternate days. 
Twenty-four hours after the last dose, tumors were harvested and snap 
frozen. Tumors embedded in OCT were sectioned (5 μm) and immu-
nofluorescence stained for hypoxia with CAIX antibody (M75 mouse 
monoclonal; ref. 61) or hypoxyprobe-1 pimonidazole antibody (clone 
4.3.11.3, Hypoxyprobe) and with cleaved caspase-3 antibody (9661, 
Cell Signaling Technology). Apoptotic cells were counted within and 
outside of hypoxic regions. LSM780 software (Carl Zeiss) was used to 
determine the average of a single cell’s surface area, and area of apop-
totic cells (expressed as percentage) in whole hypoxic or normoxic 
regions was calculated from the following formula: number of apoptotic 
cells × average area of a single cell × 100/area of total region measured. 
Images were taken from at least 2 tumors treated with vehicle and 3 
tumors treated with MK-2206. Graphs show the percentage of apoptotic 
cells from all normoxic or hypoxic regions and treatments analyzed in 
every tumor. The mean ± SEM is indicated by the bar. For the tumor 
growth curves, animals were s.c. injected with OE21 cells and random-
ized when average tumor volumes reached 100 mm3. Animals received 
vehicle or 60 mg/kg of MK-2206 on 3 alternate days, as above, and 24 
hours after the last dose, the tumors in half of the animals in each treat-
ment group were irradiated with 10 Gy. Tumors were measured regu-
larly, and tumor growth was plotted as a mean of tumor volumes ± SEM. 
The number of mice for each treatment is as follows: 5 for vehicle, 5 for 
vehicle plus IR, 6 for MK-2206, and 6 for MK-2206 plus IR.
Statistics. Statistical tests other than the ones on clinical sam-
ples were performed using GraphPad Prism 6 software (GraphPad 
Software Inc.) and are indicated in figure legends for particular 
experiments. These included 2-way ANOVA tests, 2-tailed Student’s 
t test, and log-rank (Mantel-Cox) tests. P values of less than 0.05 
were considered significant.
Study approval. All animal experiments were approved by the 
University of Oxford Biomedical Services Ethical Review Commit-
tee. Ethical approval for the analysis of human breast cancer samples 
was obtained from the Molecular Taxonomy of Breast Cancer Inter-
national Consortium.
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Immunofluorescence. Cells were grown on glass coverslips and 
stained as previously described (59). The following antibodies were 
used: PHLDA3 (ab22822, Abcam) and pAKT-S473 (4060, Cell Sig-
naling Technology). A LSM780 confocal microscope (Carl Zeiss 
Microscopy Ltd) was used. The fluorescent intensity of pAKT-S473 
per cell was measured from ≥15 randomly selected cells imaged for 
each condition and was plotted as a mean of intensities ± SEM from 3 
independent experiments.
RNA extraction, microarray analysis, and qPCR. RNA was pre-
pared using TRIzol (Invitrogen/Life Technologies). Gene expres-
sion array analysis was carried out using Agilent Sure Print HD 
arrays by Oxford Gene Technology. Differential gene expression 
regulated by p53 in hypoxia (<0.1% O2) or in normoxia (21% O2) was 
calculated as a log2(p53/p53175) of intensities, and t test with Benja-
mini and Hochberg P value adjustment was applied (60). For qPCR 
expression analysis, cDNA was reverse transcribed from total RNA 
using the Verso Kit (Thermo Scientific). qPCR was performed using 
the SYBR Green PCR Master Mix Kit (Applied Biosystems) in a 7500 
FAST Real-Time PCR thermocycler with v2.0.5 software (Applied 
Biosystems). Sequences of qPCR primers are shown in the Supple-
mental Methods. mRNA fold change was calculated using a 2–ΔΔCt 
method in relation to the 18S reference gene. The qPCR graphs show 
the mean ± SEM of 3 biological replicates.
ChIP. ChIP was carried out on HCT116 cells as described previ-
ously (7). Combined p53 antibodies (DO-I and FL-393, Santa Cruz) or 
combined nonspecific mouse and rabbit control IgGs (Cell Signaling 
Technology) were used for immunoprecipitation. For the qPCR, input 
samples were used at 100-fold dilution and ChIP samples were used at 
6-fold dilution. Fold enrichment at specific promoter sites was calcu-
lated in relation to the input samples. Primers used for qPCR are listed 
in the Supplemental Methods.
Analysis of human tumor samples. The methods, selection, and 
curation of data sets for the meta-analysis based on Gene Expression 
Omnibus cohorts have been described previously (4). Briefly, the prog-
nostic meta-analysis was carried out using the rmeta R package (http://
cran.r-project.org/). A fixed-effect model was used. The log hazard 
ratios and standard errors were obtained for each study from Cox 
proportional hazards regression. Study results were combined using 
the generic inverse-variance method. The variance was estimated as 
the square of the standard errors; this follows a χ2 distribution, with 
approximately k – 1 degrees of freedom (k = number of studies). When 
groups of genes were considered, summary expression was estimated 
both as mean and median expression. In data sets in which p53 muta-
tion status was not known, the p53 signature and related model were 
used to predict p53 mutation status as described previously (38). 
METABRIC data (39) were stratified by median expression of the gene 
signature to achieve balanced groups, and a Cox proportional hazards 
model was used to test equality of the survival distributions.
Oncomine analysis. Oncomine (https://www.oncomine.org/, 
research edition 4.4.3) results were generated using an odds ratio 2.0, 
P value of 0.01, and mRNA as a data type. No other filtering on data 
sets was applied, so the whole Oncomine cohort was used.
In vivo experiments. All animal procedures were performed in accor-
dance with current United Kingdom legislation. Female athymic nude 
mice (BALB/c nude) (Harlan) were injected s.c. in the flank with 5 × 106 
OE21 cells, 5 × 106 HCT116 cells, or 1 × 106 PSN-1 human pancreatic 
ductal carcinoma cells, the latter ones with 4 × 106 LTC-14 stellate cells. 
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